Domainex opens new Biology Centre of Excellence in Cambridge, UK
Betsy Goodfellow | February 14, 2024 | News story | Business Services | Pharmacy, domainex, facility
Domainex has announced that it has opened a new Biology Centre of Excellence at the Unity Campus at Pampisford, Cambridge, UK, in order to further support collaborations with pharmaceutical and biotechnology companies, patient foundations and academic institutions.
The facility had a grand opening on 7 February 2024, officiated by Mrs Julie Spence OBE CStJ QPM, HM Lord-Lieutenant of Cambridgeshire and attended by approximately 50 guests comprising senior biotech executives and local dignitaries.
The new facility covers three stories and 24,000 ft2, and houses a new state-of-the-art hub for life science innovation, marking a more than three-fold increase on the company’s previous footprint. It is intended that this will allow for continued, rapid expansion of people and equipment to provide innovative and customised drug discovery services.
The facility will employ over 100 scientists, including biochemists, biophysicists, cell biologists, protein scientists, bioanalysts and structural biologists.
Commenting on the opening of the facility, Mrs Julie Spence stated: “It was my pleasure to open Domainex’s new Biology Centre of Excellence and to present the King’s Award for Enterprise to Domainex’s CEO, Dr Tom Mander. The King’s Awards are the most prestigious awards available to UK businesses, and are highly competitive and only awarded to the best. I would like to congratulate Domainex on this fantastic achievement and on the opening of their new facility which will allow them to expand the high-quality, innovative drug discovery services for which they are globally renowned.”
Dr Tom Mander, chief executive officer or Domainex, added: “We are deeply honoured to receive the prestigious King’s Award from HM Lord-Lieutenant of Cambridgeshire, and are privileged that the Lord-Lieutenant has also opened our new building. Our exciting new facility will enable us to continue to expand the range of our services and will help bring much needed treatments to patients faster and more effectively.”
Betsy Goodfellow
Related Content
AbbVie invests €150m in new R&D facility in Germany
AbbVie has announced that it is investing approximately €150m in its second largest research and …
Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals
Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement …
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
